CTOs on the Move

Dicerna

www.dicerna.com

 
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.dicerna.com
  • 33 Hayden Avenue
    Lexington, MA USA 02421
  • Phone: 617.621.8097

Executives

Name Title Contact Details

Funding

Dicerna raised $70M on 03/30/2017
Dicerna raised $100M on 10/29/2018

Similar Companies

Pace Alliance

Pace Alliance is a Lawrence, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STERIS IMS

STERIS Instrument Management Services is a surgical device and instrument management and consulting company.

PrimeCare Health

Bicara

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company`s dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.

InflaRx

InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.